Advanced Nano-Cosmeceuticals
SKIN SCIENCE EVOLVED.
Sub-100nm nanoliposomes that drive Argireline 10× deeper into skin — unlocking results no ordinary serum can achieve.
<100nm
Particle Size
92%
Encapsulation
10×
Penetration
Sub-100nm nanoliposomes that drive Argireline 10× deeper into skin — unlocking results no ordinary serum can achieve.
Argireline is clinically proven to smooth expression lines. The problem is delivery. At 889 Daltons — nearly double the passive penetration limit — most of it never reaches the dermis. We engineered the solution.
At 889 Da, Argireline cannot passively cross the stratum corneum. Without a carrier system, your premium peptide stays on the surface — invisible to the skin below.
889 DaTopical peptides reach less than 5% dermal absorption unaided. That means 95 cents of every dollar spent on actives is simply washed away.
<5%Exposed Argireline is destroyed by oxidation, hydrolysis, and skin-surface proteases — degrading rapidly on contact and reducing product consistency.
UNSTABLE
Our lipid bilayer vesicles measure under 100nm — small enough to infiltrate the skin's own architecture and deliver protected peptides directly to where they're needed.
This isn't a marketing claim. It's physicochemically validated nano-delivery, confirmed by DLS particle sizing, PDI analysis, and TEM imaging of uniform spherical vesicles.
The anti-aging and premium skincare market expands relentlessly, driven by consumers demanding clinical, science-backed results over empty promises.
Absolutely. Liposomes are established — our edge is precision optimization for peptide delivery. We're not reinventing the wheel. We're engineering a better tire.
No — and that's the strategic strength. Argireline is regulatory-safe and market-validated globally. We innovate on delivery, not discovery, dramatically reducing regulatory risk.
Yes. We're actively patenting our lipid composition, encapsulation method, and stability profile — building a defensible moat against formulation commoditization.
Convincing brands to overhaul established formulation workflows is slow work with genuine resistance.
Franz diffusion data, head-to-head comparisons, and pilot brand partnerships make adoption evidence-based.
Without a patent moat, formulation copying threatens margin and competitive position.
Patents in active prosecution cover composition, method, and stability enhancement profile.
Risk of being classified as a drug, triggering a clinical trial requirement.
All marketing materials legally reviewed; cosmetics-only positioning maintained throughout.
Encapsulation process may not translate cost-effectively from lab scale to industrial volume.
15% of funds ring-fenced for scale validation before full commercial rollout begins.
Technology-first. B2B focused. IP driven. NanoArgirel is engineering the delivery infrastructure that premium cosmetic brands will depend on for the next decade.